JP2019532617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532617A5 JP2019532617A5 JP2018568709A JP2018568709A JP2019532617A5 JP 2019532617 A5 JP2019532617 A5 JP 2019532617A5 JP 2018568709 A JP2018568709 A JP 2018568709A JP 2018568709 A JP2018568709 A JP 2018568709A JP 2019532617 A5 JP2019532617 A5 JP 2019532617A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- pharmaceutical composition
- composition according
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090001123 antibodies Proteins 0.000 claims 41
- 102000004965 antibodies Human genes 0.000 claims 40
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102000007584 Prealbumin Human genes 0.000 claims 8
- 108010071690 Prealbumin Proteins 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 206010002023 Amyloidosis Diseases 0.000 claims 5
- 206010002022 Amyloidosis Diseases 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 5
- 230000001404 mediated Effects 0.000 claims 5
- 239000000523 sample Substances 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 210000001519 tissues Anatomy 0.000 claims 3
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 210000003403 Autonomic Nervous System Anatomy 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000005846 Cardiomyopathy Diseases 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 2
- 210000002216 Heart Anatomy 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 claims 2
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 2
- 206010043234 Tendon disease Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000008031 cardiomyopathy Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 206010052774 Ligament disease Diseases 0.000 claims 1
- 210000003041 Ligaments Anatomy 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 208000005198 Spinal Stenosis Diseases 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004027 cells Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 200000000009 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/201,423 US10464999B2 (en) | 2015-01-28 | 2016-07-02 | Anti-transthyretin antibodies |
US15/201,423 | 2016-07-02 | ||
PCT/IB2017/053984 WO2018007922A2 (fr) | 2016-07-02 | 2017-06-30 | Anticorps anti-transthyrétine |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019532617A JP2019532617A (ja) | 2019-11-14 |
JP2019532617A5 true JP2019532617A5 (fr) | 2020-08-13 |
JP7076711B2 JP7076711B2 (ja) | 2022-05-30 |
Family
ID=59506311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018568709A Active JP7076711B2 (ja) | 2016-07-02 | 2017-06-30 | 抗トランスサイレチン抗体 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3478714A2 (fr) |
JP (1) | JP7076711B2 (fr) |
WO (1) | WO2018007922A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3691447A4 (fr) | 2017-10-06 | 2021-08-11 | Prothena Biosciences Limited | Anticorps anti-transthyrétine |
EA202091130A1 (ru) | 2017-11-29 | 2020-08-28 | Протена Биосайенсис Лимитед | Лиофилизованный препарат моноклонального антитела к транстиретину |
MX2022014223A (es) | 2020-05-12 | 2023-04-14 | Neurimmune Ag | Terapia de combinacion para amiloidosis de la ttr. |
WO2023099788A1 (fr) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Nouveau dosage de puissance pour des médicaments à base d'anticorps et moyens utiles associés |
WO2024105062A1 (fr) | 2022-11-15 | 2024-05-23 | Neurimmune Ag | Méthodes de traitement ou de prévention de l'amylose médiée par la transthyrétine |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0832981A1 (fr) | 1987-02-17 | 1998-04-01 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
CA2124967C (fr) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Animaux transgeniques non humains capables de produire des anticorps heterologues |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
JP2002536750A (ja) | 1999-02-05 | 2002-10-29 | サムスン エレクトロニクス カンパニー リミテッド | 映像テキスチャー抽出方法及びその装置 |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
EP2298809A3 (fr) | 2001-07-12 | 2012-02-15 | FOOTE, Jefferson | Anticorps super humanisés |
WO2003057838A2 (fr) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Anticorps contre l'antigene muc18 |
KR101149777B1 (ko) | 2002-11-29 | 2012-06-11 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 신규한 네오마이신 포스포트랜스퍼라제 유전자 및 고생산성 재조합 세포의 선별 방법 |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
PT1820022E (pt) | 2004-11-10 | 2009-08-05 | Boehringer Ingelheim Pharma | Utilização de análise por citometria de fluxo para optimizar estratégias de conservação de bancos de células cho |
US8703096B2 (en) | 2006-04-21 | 2014-04-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Beta-amyloid PET imaging agents |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
PL2099823T5 (pl) | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
TWI419902B (zh) | 2007-03-02 | 2013-12-21 | 百靈佳殷格翰製藥公司 | 蛋白質產製之改良 |
EP2031064A1 (fr) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Procédé d'augmentation de titres de protéines |
US9534048B2 (en) | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
EP2953970A4 (fr) * | 2013-02-08 | 2016-06-29 | Misfolding Diagnostics Inc | Anticorps anti-transthyrétine et leurs utilisations |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI786505B (zh) * | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
-
2017
- 2017-06-30 JP JP2018568709A patent/JP7076711B2/ja active Active
- 2017-06-30 EP EP17746542.4A patent/EP3478714A2/fr active Pending
- 2017-06-30 WO PCT/IB2017/053984 patent/WO2018007922A2/fr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019532617A5 (fr) | ||
JP2019530428A5 (fr) | ||
JP2019530427A5 (fr) | ||
JP6592059B2 (ja) | アルファシヌクレインを認識するヒト化抗体 | |
JP2018506277A5 (fr) | ||
WO2021063330A1 (fr) | Anticorps de ciblage de cd3, anticorps bispécifique et son utilisation | |
JP2018510617A5 (fr) | ||
TWI673287B (zh) | 抗b7-h3抗體、其抗原結合片段及其醫藥用途 | |
JP2020536532A5 (fr) | ||
RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
RU2015136078A (ru) | Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
RU2007139953A (ru) | Антитела к ccr5 и их применение | |
RU2018124859A (ru) | Терапевтические антитела к CD47 | |
JP2017526370A5 (fr) | ||
CN109069622A (zh) | 特异性结合人cd40的拮抗性抗体和使用方法 | |
RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
EP2377555A3 (fr) | Anticorps contre le récepteur 1 du facteur de croissance endothéliale vasculaire | |
RU2015115956A (ru) | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения | |
CN104968678A (zh) | 靶向epo的抗体的组合物和方法 | |
RU2015118180A (ru) | Антитела к бета-амилоиду | |
CN105452295A (zh) | 抗血液树突细胞抗原2抗体及其用途 | |
RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
RU2018128812A (ru) | Четырехвалентные антитела к psgl-1 и их применения | |
JP2020505075A (ja) | 結合剤 | |
JP2019141084A (ja) | Baff及びb7rp1に特異的なタンパク質及びその使用 |